Abstract: A monoclonal antibody or an antibody fragment thereof is provided, in which the monoclonal antibody or the antibody fragment thereof specifically binds to a sugar chain in which a terminal sialic acid residue is bonded to galactose by an ?2,3 bond, and is not dissociated from the sugar chain after the binding to the sugar chain in which the terminal sialic acid residue is bonded to the galactose by the ?2,3 bond.

Abstract: The present invention provides a method for acquiring auxiliary information useful to assist a diagnosis or treatment of prostate cancer. The method for acquiring auxiliary information of the present invention is a method for acquiring auxiliary information to assist a diagnosis or treatment of prostate cancer, and includes a step (C) of dividing a concentration value of a prostate specific antigen having a ?-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain, contained in a sample derived from a living body, by a volume value of prostate of the living body to calculate the concentration value of the GalNAc-PSA per prostate volume.

Abstract: The present invention provides methods that are for acquiring various types of supplementary information used for diagnosis or treatment of prostate cancer, and that can be implemented in a less-invasive manner at a low cost. Provided are, by measuring the content of prostate specific antigen (PSA) having a ?-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a specimen, and comparing the measured value with a threshold value, (1) a method for estimating whether a Gleason score (primary pattern and secondary pattern) is not less than or less than a prescribed value, (2) a method for estimating whether the pathological stage (pT) is not less than or less than a prescribed value, and (3) a method for acquiring information for assessment indicating diagnosis or treatment should be actively conducted because a GS at gross total removal is expected to be higher than a GS at biopsy.

Abstract: The present invention relates to a method for determining prostate carcinoma, including obtaining a ratio 1 between an amount of a free prostate specific antigen and an amount of a free PSA having an ?(2,3) glycan, the free PSA having an ?(2,3) glycan being a free prostate specific antigen having a glycan in which a terminal sialic acid residue of the glycan is ?(2,3)-linked to a second galactose residue from a terminal of the glycan, in a sample derived from a subject; obtaining a ratio 2 between the ratio 1 and a volume of the prostate of the subject; and determining prostate carcinoma based on the obtained ratio 2.

Abstract: The purpose of the present invention is to provide a 10B medicine that can be selectively accumulated in tumor tissues at a low dose in a short time, and can be applied to BNCT. The 10B medicine comprises a compound containing: a peptide capable of selectively binding to tumor vascular endothelial cells; and 10B, wherein the 10B medicine is administered to a subject suffering from cancer at a dose of 300-600 mg per administration, and is accumulated after the administration such that the concentration of 10B in the cancer tissue of the subject becomes 1 ppm or higher.

Abstract: The present invention provides methods that are for acquiring various types of supplementary information used for diagnosis or treatment of prostate cancer, and that can be implemented in a less-invasive manner at a low cost. Provided are, by measuring the content of prostate specific antigen (PSA) having a ?-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a specimen, and comparing the measured value with a threshold value, (1) a method for estimating whether a Gleason score (primary pattern and secondary pattern) is not less than or less than a prescribed value, (2) a method for estimating whether the pathological stage (pT) is not less than or less than a prescribed value, and (3) a method for acquiring information for assessment indicating diagnosis or treatment should be actively conducted because a GS at gross total removal is expected to be higher than a GS at biopsy.

Abstract: The present invention relates to a method for acquiring auxiliary information for diagnosis and treatment (medical care) of prostate cancer. A method for acquiring medical care auxiliary information for estimating a risk of prostate cancer recurrence with a specimen of prostate tissue, wherein an at least three-stage evaluation score is used to express a quantity of biological material in a tumor site of the specimen, the biological material having a ?-N-acetylgalactosamine residue at a nonreducing terminal of a sugar chain.

Abstract: An automatic analyzing apparatus 10 includes a chip rack 11 that stores a pipette chip, a pipette 12 into which a specimen is injected, a conveyance unit that conveys the pipette 12 by parallel translation, a reagent rack 14, a reaction unit 15, a detection unit 16, and a detection block unit 17. The pipette chip stored by the chip rack 11 has a planar structure to directly and optically detect the specimen. The chip rack 11 includes, in a hole that receives the pipette chip, a guide corresponding to the structure of the pipette chip. The pipette 12 sucks or discharges the specimen via the pipette chip mounted onto the tip thereof by a drive of a pump. In the detection unit 16, a measurement is carried out with the pipette chip arranged so that the plane that receives light is vertical to an optical axis.

Abstract: The method for distinguishing between prostate carcinoma and benign prostatic hyperplasia comprising: bringing an analyte sample containing a prostate-specific antigen (PSA) into contact with a carrier having an anti-free PSA antibody immobilized thereon, thereby binding free PSA to the anti-free PSA antibody immobilized on the carrier; thereafter bringing the carrier in which the free PSA is bound to the immobilized anti-free PSA antibody into contact with a monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an ?(2,3) bond, thereby binding the monoclonal antibody recognizing the glycan to the free PSA bound to the anti-free PSA antibody; measuring the amount of the free PSA having an N-type glycan in which a terminal sialic acid residue is bound to galactose through an ?(2,3) bond; comparing the measured amount thus obtained with a preset cutoff value for prostate carcinoma and benign prostatic hyperplasia, thereby determinin

Abstract: An automatic analyzing apparatus 10 includes a chip rack 11 that stores a pipette chip, a pipette 12 into which a specimen is injected, a conveyance unit that conveys the pipette 12 by parallel translation, a reagent rack 14, a reaction unit 15, a detection unit 16, and a detection block unit 17. The pipette chip stored by the chip rack 11 has a planar structure to directly and optically detect the specimen. The chip rack 11 includes, in a hole that receives the pipette chip, a guide corresponding to the structure of the pipette chip. The pipette 12 sucks or discharges the specimen via the pipette chip mounted onto the tip thereof by a drive of a pump. In the detection unit 16, a measurement is carried out with the pipette chip arranged so that the plane that receives light is vertical to an optical axis.

Abstract: An object of the present invention is to provide a method for distinguishing between prostate carcinoma and benign prostatic hyperplasia with high sensitivity and good reproducibility using a small amount of an analyte sample.

Abstract: The present invention provides a novel method for diagnosing renal cell carcinoma. The method of the invention allows evaluation of the presence of renal cell carcinoma or the degree of malignancy of renal cell carcinoma, by conducting comprehensive analysis of N-linked sugar chains in serum of a patient and utilizing an expression level of detected sugar chain as an index of the evaluation.

Abstract: It is to provide a method and a kit for detecting the prognosis of cancer at high accuracy in a simple and rapid manner at low cost. The method is specifically a method for detecting the prognosis of cancer, at least including a step of detecting core-2 ? 1,6-acetylglucosaminyltransferase in a sample collected from a biological organism to examine the relationship between the results of the detection and the prognosis of cancer in the biological organism, wherein core-2 ?1,6-acetylglucosaminyltransferase is preferably core-2 ?1,6-acetylglucosaminyltransferase-I; the biological organism is preferably human body; and the sample is preferably a living tissue.